Renalytix (Reg S) (RENX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

7.15p
   
  • Change Today:
    -0.096p
  • 52 Week High: 12.50p
  • 52 Week Low: 5.62p
  • Currency: UK Pounds
  • Shares Issued: 437.02m
  • Volume: 0
  • Market Cap: £31.26m
  • RiskGrade: 348
  • Beta: 0.59

RENX Overview

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

Key Personnel

CEO: James Renwick McCullough
Chief Technical Officer: Fergus Fleming
Non-Executive Chairman: Christopher H B Mills
Non-Executive Dir: Catherine Coste, Robert (Rob) Graham Naylor, Erik Kristian Lium

Contact Details

Address: 2 Leman Street, London, United Kingdom, E1W 9US
Website: http://www.renalytix.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BYWL4Y04

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

RENX Market Data

Currency UK Pounds
Share Price 7.15p
Change Today -0.096p
% Change -1.33 %
52 Week High 12.50p
52 Week Low 5.62p
Volume 0
Shares Issued 437.02m
Market Cap £31.26m
Beta 0.59
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

RENX Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page